Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Second Pfizer COVID-19 Vaccine Dose in Allergic Individuals
NCT04977479Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine at 3 hours. Started Sep 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04977479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977479.